Printer Friendly

Japan : Eisai Enters Into Licensing Agreement With Adlai Nortye for Potential Anticancer Agent E7046 (Prostaglandin E2 Receptor Type 4 Antagonist).

Eisai Co., Ltd announced today that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisais in-house discovered potential anticancer agent E7046, which is an investigational prostaglandin E2 (PGE2) type EP4 receptor antagonist, to Adlai Nortye Biopharma Co., Ltd. (Headquarters: Hangzhou, China, Adlai Nortye) in all regions outside of Japan and part of Asia (excluding China). E7046 is an orally administered, selective EP4 receptor antagonist discovered by Eisais U.S. Andover research facility. It is suggested that PGE2 signals through EP4 receptors may suppress the antitumor activity of immune cells.

By inhibiting EP4, E7046 is expected to act on the tumor microenvironment via a different mechanism to immune checkpoint inhibitors to potentially demonstrate antitumor effects. Currently, E7046 is being investigated as a monotherapy in a Phase I clinical study as well as a Phase Ib clinical study in combination with radiotherapy/chemoradiotherapy. Under this agreement, Eisai will receive from Adlai Nortye a one-time payment, milestone payments in accordance with the progress of development, as well as certain royalties according to sales revenue after launch.

Adlai Nortye is a science-led clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing new and effective immunotherapy for patients with cancer. Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. By licensing E7046 to Adlai Nortye, which is developing several tumor immunotherapies that have synergies with E7046, Eisai aims to maximize the value of the agent in order to hopefully contribute to the treatment of patients in the future who need tumor immunotherapies as soon as possible.

[c] 2017 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2018 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:9CHIN
Date:Jan 20, 2018
Previous Article:Austria,Uganda : IAEA Helps Uganda Restart Vital Radiotherapy Services for Cancer Patients.
Next Article:United States : Gardner votes AGAINST Government Shutdown and FOR Six Years of CHIP Funding for Colorado's Children.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters